Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with calls leading puts 3:2. Implied volatility suggests the market is anticipating a move near 4.2%, or $1.40, after results are released. Median move over the past eight quarters is 8.2%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Deramiocel’s De‑Risked Path to Approval and Expanded DMD Opportunity Underpin Buy on CAPR
- Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial
- Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
- Capricor Advances Deramiocel BLA Review for Duchenne DMD
- Capricor announces establishment of new PDUFA date for dermiocel BLA